ProQR Therapeutics NV 2017 AR2
The report highlights ProQR's progress in 2017, focusing on the development of its pipeline of transformative RNA medicines for severe genetic rare diseases. Key achievements include positive Phase 1b clinical data for eluforsen in cystic fibrosis patients and the initiation of a Phase 1/2 trial for QR-110 in Leber's congenital amaurosis 10. Additionally, the company introduced its novel Axiomer RNA editing platform technology, validating it with in vivo proof of concept. Financially, ProQR ended the year with ‐48.1 million in cash and cash equivalents while continuing to invest in its research and development programs.
Company: ProQR Therapeutics NV
Sector: Health Care
Country: Netherlands
Year: 2017
Type: AR2
Pages: 124
Back to company
ProQR Therapeutics NV
Annual Report
The report highlights ProQR's progress in 2017, focusing on the development of its pipeline of transformative RNA medicines for severe genetic rare diseases. Key achievements include positive Phase 1b clinical data for eluforsen in cystic fibrosis patients and the initiation of a Phase 1/2 trial for QR-110 in Leber's congenital amaurosis 10. Additionally, the company introduced its novel Axiomer RNA editing platform technology, validating it with in vivo proof of concept. Financially, ProQR ended the year with ‐48.1 million in cash and cash equivalents while continuing to invest in its research and development programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees